Egypt HIV Drugs Market Analysis Report 2022 to 2030

Egypt HIV Drugs Market Analysis

$ 3999

Egypt HIV Drugs Market is at around $88.76 Mn in 2023 and is projected to reach $125.73 Mn in 2030, exhibiting a CAGR of 5.1% during the forecast period. The market is growing due to increased awareness, government initiatives, and international collaborations & funding. The market is dominated by key players like EVA Pharma, Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffmann-La Roche Ltd., and Novartis.

ID: IN10EGPH011 CATEGORY: Pharmaceuticals GEOGRAPHY: Egypt AUTHOR: Aneri Parekh

Buy Now

Egypt HIV Drugs Market Executive Summary

Egypt HIV Drugs Market is at around $88.76 Mn in 2023 and is projected to reach $125.73 Mn in 2030, exhibiting a CAGR of 5.1% during the forecast period.

Medication for the management and treatment of HIV/ AIDS within the Egyptian healthcare system is supplied by the HIV medicine market in Egypt. This market includes a range of supportive pharmaceuticals, treatments, and antiretroviral medications that are intended to battle HIV and enhance the quality of life for patients. The dynamics of this industry in Egypt are greatly influenced by an array of factors, including ongoing research, healthcare infrastructure, government initiatives, and pharmaceutical accessibility.

The market for HIV medications in Egypt is expanding steadily owing to government initiatives, rising public awareness, and easier access to healthcare. To meet the rising demand for HIV medications, major players in the market are growing their presence and launching new treatments. However, issues like the stigma associated with HIV/ AIDS and the inadequate healthcare infrastructure in rural areas continue to impede market expansion.

As a result of the rapid growth in sales of HIV drugs, the market was estimated to be worth $31.7 Bn in 2023. An increase in HIV diagnoses is the main factor fueling this growth. Increased competition and the appearance of more generic alternatives are causing the market to change. Reducing the stigma associated with HIV, removing financial barriers to treatment, and offering support services are essential to improving therapy accessibility in developing countries.

With a significant market share in HIV medications, EVA Pharma is a well-known pharmaceutical company in Egypt. Antiretrovirals (ARVs) and other necessary medications are produced by EVA Pharma along with a variety of generic HIV medications. This contributes to the nation's steady supply of reasonably priced HIV treatment. EVA Pharma has collaborated with multiple entities, such as UNAIDS and the Egyptian Ministry of Health, to initiate HIV awareness initiatives and enhance treatment accessibility. They started the "Zay Ay Marad" campaign in November 2022 to eliminate the stigma associated with HIV/ AIDS and combat discrimination against those who have the virus. EVA Pharma is dedicated to the research and creation of novel HIV medications and technologies. This involves working together with foreign partners to create new and enhanced ARVs.

Egypt HIV drugs market

Market Dynamics

Market Growth Drivers:

Increasing Awareness: As Egypt's awareness of HIV/ AIDS and the significance of treatment grows, more people seek testing and treatment, increasing HIV drug demand.

Government Initiatives: Increased government investment in HIV/ AIDS testing and treatment programs can boost market growth by boosting HIV medication access.

International Funding and Partnerships: International collaboration and HIV/ AIDS program funding help Egypt to obtain and distribute HIV medications, driving market growth.

Market Restraints:

Discrimination and Stigma: In Egypt, stigma around HIV/ AIDS continues to be a major obstacle to receiving care. People may be discouraged from obtaining HIV testing, treatment, and support services out of fear of prejudice and social rejection.

Treatment Affordability: Many patients, particularly those from low-income backgrounds or without sufficient health insurance coverage, may find it difficult to afford the high cost of HIV medications and related healthcare services.

Problems with Supply Chain: Interruptions or delays in the HIV drug supply chain can affect the availability of medications, causing patients to receive subpar treatment and experience less-than-ideal health outcomes.

Healthcare Policies and Regulatory Landscape

To safeguard public health, the Egyptian Drug Authority (EDA), a pharmaceutical regulatory body under the Egyptian Ministry of Health (MOH), is in charge of making sure pharmaceutical products are safe and of high quality. To legally market pharmaceutical products in Egypt, applicants must submit adequate data from each section demonstrating the product's safety and efficacy for the purposes specified in the suggested labeling to the Egyptian Drug Authority. The intricate web of documents, departments, and processes involved may capture applicants in red tape and uncertainty. Navigating this bureaucratic labyrinth frequently necessitates the expertise of local specialists who are familiar with the peculiarities and practices of the nation.

Competitive Landscape

Key Players:

EVA Pharma
Gilead Sciences
ViiV Healthcare
Boehringer Ingelheim International GmbH
Janssen Pharmaceuticals
Merck & Co.
Bristol-Myers Squibb
AbbVie Inc.
F. Hoffmann-La Roche Ltd
Novartis

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Drugs Market Segmentation

By Drug Class

Integrase Inhibitors
Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Combination HIV Medicines
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.